Latest News-BUCHAN CONSULTING PTY LTD Mediaroom_Page

Triad Life Sciences completes A$25m funding round, anticipates ASX listing in coming months

MEMPHIS, Tenn., Aug. 29, 2021 /PRNewswire/ -- Innovative US based biotech companyTriad Life Science...

2021-08-30 09:18 1339

Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's

MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (...

2021-08-04 20:39 24630

Appendix 4C - Q4 FY21 Quarterly Cash Flow Report

Highlights: * Positive Guidance from European Medicines Agency for ATH434 Phase 2 Clinical Trial...

2021-07-30 21:05 14472

Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function

MELBOURNE, Australia, July 15, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...

2021-07-15 21:52 36473

Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's

MELBOURNE, Australia and SAN FRANCISCO, July 1, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...

2021-07-01 19:50 13000

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

Highlights: * Alterity receives positive guidance from the European Medicines Agency's Committee...

2021-06-23 21:21 14648

Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report

Highlights: * Michael J. Fox Foundation grants Alterity $US495K for Parkinson's disease research...

2021-04-29 20:30 5589

SenSen: North American Operations and Expansion Update

HIGHLIGHTS * SenSen's Annual Recurring Revenue (ARR) from North America to exceed A$1.5M per...

2021-04-22 09:00 3930

ATH434 protects brain cells and improves motor function in Parkinsonian disorder

MELBOURNE, Australia , April 21, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE...

2021-04-21 20:11 2230

Alterity to present at the 7th International Congress of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited...

2021-02-26 20:45 6027

Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials

NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" o...

2021-02-09 21:53 3290

Medibio Granted CE Mark Approval for MEBsleep

MINNEAPOLIS, Jan. 19, 2021 /PRNewswire/ -- Medibio Limited (MEB or the Company )(ASX: MEB)(OTCPINK: ...

2021-01-19 21:06 4818

Dr David Stamler Appointed CEO

MELBOURNE, Australia, Jan. 7, 2021 /PRNewswire/ -- The Board of Alterity Therapeutics (ASX: ATH, NA...

2021-01-07 21:00 11586

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...

2020-12-22 05:42 5543

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...

2020-11-17 01:09 1253

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...

2020-11-16 21:42 2639

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: A...

2020-10-27 10:03 3373

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

MELBOURNE, Australia, Oct. 26, 2020 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters:Tokyo, CEO: Haruo...

2020-10-26 08:37 1706

Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

New data independently confirms and extends laboratory findings and expands safety profile of ATH434

MELBOURNE, Australia and SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...

2020-08-04 09:33 7431

Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report

Highlights: * FDA provides guidance for ATH434 development pathway * Company compliant with min...

2020-07-31 06:49 16797